SBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006

Similar documents
ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ

Metoprolol Succinate SelokenZOC

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Egyptian Hypertension Guidelines

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Treating Hypertension in Individuals with Diabetes

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Management of Hypertension. Ahmed El Hawary MD Suez Canal University

Managing Hypertension in the Perioperative Arena

Hypertension and CAD. Dr. Vinod Sharma. National Heart Institute New Delhi

Acute Coronary Syndrome. Sonny Achtchi, DO

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Combination Therapy for Hypertension

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Objectives. Identify early signs and symptoms of Acute Coronary Syndrome Initiate proper protocol for ACS patient 10/2013 2

Heart Failure Clinician Guide JANUARY 2018

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Management of Hypertension

Prevention of Cardiovascular Events in Hypertension and CAD & Management of Hypertension in HF of Ischemic origin

Hypertension Update 2009

Managing HTN in the Elderly: How Low to Go

Hypertension Update Clinical Controversies Regarding Age and Race

2010 ACLS Guidelines. Primary goals of therapy for patients

Μαρία Μαρκέτου Επιμ. Α Καρδιολογική Κλινική ΠαΓΝΗ

Chapter (9) Calcium Antagonists

Στόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων

Categories of HTN. Overview of Hypertension. Types of Hypertension

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Hypertension (JNC-8)

Non ST Elevation-ACS. Michael W. Cammarata, MD

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

Hypertension Management Focus on new RAAS blocker. Disclosure

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

DECLARATION OF CONFLICT OF INTEREST. None

Hypertensives Emergency and Urgency

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

Practitioner Education Course

Adult Diabetes Clinician Guide NOVEMBER 2017

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

The Latest Generation of Clinical

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Update in Hypertension

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Blood Pressure Treatment in 2018

Heart Failure Clinician Guide JANUARY 2016

LXIV: DRUGS: 4. RAS BLOCKADE

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP

Alex versus Xience Registry Preliminary report

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

By Prof. Khaled El-Rabat

Hypertension Pharmacotherapy: A Practical Approach

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Abbreviations Cardiology I

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

TREATMENT OF HYPERTENSION

Update on Current Trends in Hypertension Management

Medical Management of Acute Heart Failure

HYPERTENSION. Background for understanding the Hypertension literature. Case presentation. Approach to Treatment. Jeffrey J. Kaufhold, MD Nephrology

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Antihypertensive drugs: I. Thiazide and other diuretics:

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United

Acute Coronary Syndromes

Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient

Difficult to Treat Hypertension

Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC

Byvalson. (nebivolol, valsartan) New Product Slideshow

BLOOD PRESSURE-LOWERING TREATMENT

How would you manage Ms. Gold

Hypertension and Cardiovascular Disease

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Blood Pressure Management in Acute Ischemic Stroke

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Incidental Findings; Management of patients presenting with high BP. Phil Swales

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki

Hypertensive Crises. Controlling high blood pressure prevents disease. Recognition and Management of Acute Hypertensive Emergencies

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

How clinically important are the results of the large trials in hypertension?

Patient is healthy with no chronic disease or significant risk factors [16%].

Hypertension JNC 8 (2014)

ST-elevation myocardial infarctions (STEMIs)

First line treatment of primary hypertension

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

Adult Blood Pressure Clinician Guide June 2018

Acute coronary syndromes

Objectives. Describe results and implications of recent landmark hypertension trials

hypertension Head of prevention and control of CVD disease office Ministry of heath

Hypertension Management Controversies in the Elderly Patient

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

Transcription:

Management of Hypertension in Patients with CAD M. Mohsen Ibrahim, MD Cardiology Department- Cairo University 1. What is the optimal BP in patients with hypertension and CAD? 2. What is the minimum safe level of DBP? 3. Do particular classes of drugs have protective actions beyond BP lowering? 4. Which antihypertensive drugs should be used in patients with established CAD? Stable angina. Unstable angina and non-st- elevation MI. ST-elevation MI. ١

The optimal BP in patients with hypertension and CAD CAD Prevention High CAD risk Stable angina UA/ NSTEMI STEMI LVD BP Target (mmhg) < 140/90 <130/80 <130/80 <130/80 <130/80 < 120/80 High CAD Risk Diabetes mellitus. Chronic kidney disease. Known CAD CAD equivalent: Carotid artery disease. Peripheral artery disease. Abdominal aortic aneurysm. 10-year Framingham risk score 10%. Metabolic syndrome ٢

CAMELOT Trial Blood Pressure and Coronary Disease Progression : IVUS SBP in range of 120 to 140 :no progression or regression of CAD Sipahi et al., 2006 Minimal Safe DBP In patients with high DBP and occlusive CAD with evidence of ischemia: Increased MI prevalence in those with achieved DBP of < 80 mmhg (Medical Research Council s Trial of mild hypertension) BP should be lowered slowly. Falls of DBP below 60 mmhg should be avoided if the patient has diabetes or is over the age of 60 years. ٣

Antihypertensive Drugs Mechanism Independent of the BP Lowering Effect Greater Anti-atherosclerotic Action Has not been demonstrated convincingly. For secondary prevention (CAD, CKD, or recurrent stroke): Not all drug classes has been proven to confer optimal benefit. Which Drug Class to Use in CAD Patients? INVEST Study Verapamil- Trandolapril was as clinically effective as atenolol- hydrochlorothiazide in hypertensive CAD patients- similar event rates. Primary outcome: death (all cause), non fatal MI, non fatal stroke after 24 months JAMA 2003 ٤

Hypertension in Patients with CAD Stable angina B-blockers: drugs of first choice. CCB: - added to BB when: 1. BP remains elevated 2. Angina persists - Substitute BB when: 1. Contraindication 2. Side effects ACE-I: high risk pateints (diabetes, LV syst dysfunction). ARBs: patients intolerant to ACE-I B-Blockers: Blockers: Indications Symptomatic CAD (angina) MI LV dysfunction ٥

ACE-inhibitors: Indications All patients after MI All patients with LV dysfunction Patients at high risk of CAD High risk CAD patients (diabetes, other risk factors) ACE-inhibitors: Clinical Trials Cardioprotection Definite HOPE EUROPA ANBP-2 No special advantage PEACE ALLHAT ٦

Hypertension in Patients with CAD Unstable angina and NSTEMI In patients presenting with persistent pain, and in absence of contraindications - BB should be started intravenously, followed by oral BB. - Cardioselective BB without ISA are preferably. - BB can be given to patients with mild to moderate reactive airway disease. - Non dihydropyridine CCB when BB are contraindicated. CCB in ACS Clinical Trials DAVIT (Danish Verapamil Infarction Trials) Reduction in death or non-fatal MI IV verapamil at admission and then orally for 1 week. DRS (Diltiazem Reinfarction Study) Reduction in reinfarction and refractory angina at 14 days Diltiazem 24-72 hrs after onset of NSTEMI. Avoid verapamil and diltiazem in patients with LV dysfunction. ٧

ACS- STEMI Principles therapy of HTN are similar to those for U/A and NSTEMI. Appropriate of treatment of HTN at presentation with STEMI - Few data are available. HTN is a relative contraindication to fibrinolysis IV nitroglycemia: - Acute HTN - Relieve ischemic pain - Pulmonary congestion IV BB: -Reduction in: - reinfarction and vent fibrillation. - Increase in cardiogenic shock Early ACE-I: particularly in ant MI, LV dysfunction, persistent HTN Acute severe HTN and Flash Pulmonary Edema IV Nitroglycerin No Tachycardia Tachycardia ± ischemia IV furosomide ACE-I: short acting IV esmolol IV furosomide IV nitroprusside ٨

HTN in HF of Ischemic Origin Limited evidence-based guidelines Patients presenting with HF: -older - more than half have a normal LVF Increased LV mass is associated with development of depressed LVF Drugs of choice: Thiazide diuretics + ACE-I Target BP: < 120/80 mmhg Drugs to avoid: Non dihydropyridine CCB Moxonidine and clonidine α-blockers to be used with caution Which Drug Class to Use in specific CAD Patients? Based on Additional Factor History of HF Diabetes risk Physician's best judgment ٩